
|Videos|November 10, 2017
Using Antibody-Mediated Neutralization of Soluble MIC to Enhance Response to CTLA-4 Blockade
Author(s)Jennifer Wu, PhD
Jennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Advertisement
Jennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32ndAnnual Meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
3
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
4
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
5



































